Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. Now, the U.K.-based pharma is overseeing a range of clinical trials to ...

Lead program obexelimab is designed to bind to CD19 and Fc gamma receptor IIb, both of them targets expressed on B cells. A Phase 3 test is underway in immunoglobulin G4-related disease ...

Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease pathogenesis. In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled ...

Credit: Getty Images In a phase 3 clinical trial, researchers assessed the efficacy and safety of inebilizumab in patients with generalized myasthenia gravis. At Week 26, compared to the placebo ...

IMPT-314 is a dual-targeting CD19/20 CAR T cell candidate for hematologic malignancies, including B-cell non-Hodgkin’s lymphoma. Lyell had 300 overall employees as of Dec. 31, according to a March 11 ...

Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in ...

From the Department of Cardiology and Angiology I, University Heart Center Freiburg, Germany (D.W.) Faculty of Medicine, University of Freiburg, Germany (D.W.) K. Ley has received research funding for ...

Anti-CD47 or Aβ inhibitor restore immunity, reduce bacterial load/organ damage, and improve survival. Downregulated adaptive immunity genes (e.g., Pax5, CD19) potentially distinguish sepsis from ...

Department of Pharmacology and Toxicology (O.T.H., N.C., E.D., L.M.A., D.W., K.W., T.W.T., E.H.C., S.B., G.W.B., D.C.C., B.L.), University of Mississippi Medical ...

2023年CDE发布《基因治疗非临床研究指导原则》，通过明确技术标准释放政策红利，推动实体瘤（如Claudin18.2靶点IND增长300%）、自身免疫疾病（CD19 CAR ...